

Martin J Landray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/788054/publications.pdf>

Version: 2024-02-01

119
papers

32,227
citations

53660

45
h-index

21474

114
g-index

134
all docs

134
docs citations

134
times ranked

48822
citing authors

#	ARTICLE	IF	CITATIONS
1	Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 693-704.	13.9	8,063
2	UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. <i>PLoS Medicine</i> , 2015, 12, e1001779.	3.9	6,753
3	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet, The</i> , 2011, 377, 2181-2192.	6.3	2,087
4	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1330.	3.8	1,855
5	Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. <i>New England Journal of Medicine</i> , 2014, 371, 203-212.	13.9	1,367
6	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2030-2040.	13.9	1,013
7	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1217-1227.	13.9	780
8	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011, 79, 1331-1340.	2.6	609
9	HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. <i>European Heart Journal</i> , 2013, 34, 1279-1291.	1.0	581
10	Lopinavirâ€“ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2020, 396, 1345-1352.	6.3	569
11	COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. <i>Lancet, The</i> , 2020, 396, 381-389.	6.3	521
12	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	6.3	512
13	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	3.8	498
14	Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 806-812.	2.2	400
15	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018, 137, 961-972.	1.6	368
16	The Magic of Randomization versus the Myth of Real-World Evidence. <i>New England Journal of Medicine</i> , 2020, 382, 674-678.	13.9	296
17	Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. <i>American Journal of Kidney Diseases</i> , 2004, 43, 244-253.	2.1	272
18	Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 199-208.	3.7	244

#	ARTICLE	IF	CITATIONS
19	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 829-839.	5.5	234
20	Analyses of Cancer Data from Three Ezetimibe Trials. <i>New England Journal of Medicine</i> , 2008, 359, 1357-1366.	13.9	230
21	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , 2015, 66, 602-612.	2.1	210
22	Feasibility of Obtaining Measures of Lifestyle From a Smartphone App. <i>JAMA Cardiology</i> , 2017, 2, 67.	3.0	207
23	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 749-761.	1.4	196
24	First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2005, 45, 473-484.	2.1	184
25	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514.	1.6	145
26	Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1082-1094.	2.1	144
27	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1825-1833.	3.0	142
28	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2015-2027.	3.0	140
29	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , 2015, 66, 591-601.	2.1	138
30	Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. <i>Lancet</i> , 2014, 384, 1684-1690.	6.3	124
31	Trends in the Incidence and Recurrence of Inpatient-Treated Spontaneous Pneumothorax, 1968-2016. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1471.	3.8	107
32	The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 385-395.	2.1	104
33	Randomized Clinical Trials "Removing Unnecessary Obstacles. <i>New England Journal of Medicine</i> , 2013, 369, 1061-1065.	13.9	103
34	Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. <i>American Journal of Kidney Diseases</i> , 2001, 38, 537-546.	2.1	97
35	A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1858-1863.	1.2	82
36	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. <i>BMC Nephrology</i> , 2015, 16, 65.	0.8	82

#	ARTICLE	IF	CITATIONS
37	Nepriylsin inhibition in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 738-743.	0.4	80
38	Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e25920.	1.1	70
39	Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review. <i>Digital Biomarkers</i> , 2018, 2, 11-30.	2.2	70
40	Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001696.	1.6	65
41	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 747-754.	1.0	62
42	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 68, 371-380.	2.1	57
43	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2014, 64, 40-48.	2.1	55
44	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. <i>Seminars in Dialysis</i> , 2015, 28, 35-47.	0.7	49
45	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. <i>American Journal of Kidney Diseases</i> , 2019, 73, 206-217.	2.1	49
46	Enhancing clinical evidence by proactively building quality into clinical trials. <i>Clinical Trials</i> , 2016, 13, 439-444.	0.7	45
47	Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study. <i>Scientific Data</i> , 2019, 6, 24.	2.4	43
48	Cross-Sectional Analysis of Abnormalities of Mineral Homeostasis, Vitamin D and Parathyroid Hormone in a Cohort of Pre-Dialysis Patients. <i>Nephron Clinical Practice</i> , 2007, 107, c109-c116.	2.3	42
49	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. <i>American Journal of Kidney Diseases</i> , 2016, 67, 31-39.	2.1	42
50	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 546-552.	2.2	41
51	Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 625.	3.8	40
52	Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. <i>Nature Communications</i> , 2021, 12, 915.	5.8	40
53	Conventional and Genetic Evidence on the Association between Adiposity and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 127-137.	3.0	39
54	Homocysteine, renal function, and risk of cardiovascular disease. <i>Kidney International</i> , 2003, 63, S131-S133.	2.6	37

#	ARTICLE	IF	CITATIONS
55	Serum Free Light Chains and the Risk of ESRD and Death in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2829-2837.	2.2	35
56	Impact of <i>ADCY9</i> Genotype on Response to Anacetrapib. <i>Circulation</i> , 2019, 140, 891-898.	1.6	34
57	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	2.6	32
58	Making trials part of good clinical care: lessons from the RECOVERY trial. <i>Future Healthcare Journal</i> , 2021, 8, e243-e250.	0.6	32
59	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 314-322.	1.3	30
60	Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials. <i>Trials</i> , 2020, 21, 734.	0.7	30
61	Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. <i>European Heart Journal</i> , 2020, 41, 3336-3342.	1.0	27
62	Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. <i>European Heart Journal</i> , 2022, 43, 1416-1424.	1.0	27
63	Impact of CKD on Household Income. <i>Kidney International Reports</i> , 2018, 3, 610-618.	0.4	25
64	A Practical Method of Measuring Glomerular Filtration Rate by Iohexol Clearance Using Dried Capillary Blood Spots. <i>Nephron Clinical Practice</i> , 2007, 106, c104-c112.	2.3	24
65	Lipid-lowering drugs and homocysteine. <i>Lancet, The</i> , 1999, 353, 1974-1975.	6.3	23
66	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials. <i>Seminars in Dialysis</i> , 2007, 20, 498-503.	0.7	23
67	Realising the full potential of data-enabled trials in the UK: a call for action. <i>BMJ Open</i> , 2021, 11, e043906.	0.8	23
68	Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men. <i>Journal of Internal Medicine</i> , 2010, 268, 145-154.	2.7	22
69	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1794-1801.	2.2	22
70	Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. <i>Transplantation Research</i> , 2013, 2, 7.	1.5	21
71	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. <i>Heart</i> , 2017, 103, 1880-1890.	1.2	21
72	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. <i>Kidney International</i> , 2018, 93, 1165-1174.	2.6	21

#	ARTICLE	IF	CITATIONS
73	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 914-919.	2.2	19
74	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 67, 576-584.	2.1	19
75	Biliary Tract and Liver Complications in Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2738-2748.	3.0	19
76	Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , 2017, 38, 1632-1637.	1.0	19
77	Which cardiovascular risk factors matter in chronic kidney disease?. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 9-11.	0.4	18
78	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial. <i>American Journal of Transplantation</i> , 2018, 18, 1424-1434.	2.6	18
79	Testing the practical aspects of therapeutics by objective structured clinical examination. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 263-266.	0.7	16
80	Clinical Trials: Rethinking How We Ensure Quality. <i>Drug Information Journal</i> , 2012, 46, 657-660.	0.5	16
81	Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes. <i>JAMA Network Open</i> , 2019, 2, e190223.	2.8	16
82	A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction. <i>Journal of Internal Medicine</i> , 2000, 248, 316-318.	2.7	15
83	Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 601-605.	1.0	15
84	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK. <i>JAMA Network Open</i> , 2021, 4, e2139748.	2.8	15
85	The cardioprotective role of beta-blockers in patients with diabetes mellitus. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002, 27, 233-242.	0.7	14
86	LIPIDS IN CHRONIC KIDNEY DISEASE. <i>Journal of Renal Care</i> , 2010, 36, 27-33.	0.6	14
87	Increasing the use of mobile technology-derived endpoints in clinical trials. <i>Clinical Trials</i> , 2018, 15, 313-315.	0.7	14
88	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179.	2.6	13
89	Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 249-258.	1.8	13
90	The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1671-1681.	1.4	12

#	ARTICLE	IF	CITATIONS
91	Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2â€“Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. <i>Clinical Therapeutics</i> , 2019, 41, 1767-1777.	1.1	12
92	A decade of the Clinical Trials Transformation Initiative: What have we accomplished? What have we learned?. <i>Clinical Trials</i> , 2018, 15, 5-12.	0.7	11
93	Challenges of linking to routine healthcare records in UK Biobank. <i>Trials</i> , 2015, 16, .	0.7	10
94	Oxidative stress after thrombolysis. <i>Lancet</i> , The, 1998, 352, 960.	6.3	9
95	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. <i>International Journal of Obesity</i> , 2020, 44, 2256-2266.	1.6	9
96	Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. <i>American Journal of Cardiology</i> , 2000, 86, 126.	0.7	8
97	Dual blockade of the renin-angiotensin system: are two better than one?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3602-3607.	0.4	8
98	Randomized Clinical Trials â€” Removing Obstacles. <i>New England Journal of Medicine</i> , 2013, 369, 2268-2269.	13.9	8
99	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 348-354.	0.9	8
100	Accelerometer-measured physical activity and functional behaviours among people on dialysis. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 950-958.	1.4	8
101	Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments. <i>Trials</i> , 2022, 23, 62.	0.7	8
102	Niacin for Reduction of Cardiovascular Risk. <i>New England Journal of Medicine</i> , 2014, 371, 1940-1944.	13.9	7
103	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw396.	0.4	6
104	Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic?. <i>European Heart Journal</i> , 2020, 41, 2140-2144.	1.0	5
105	Cardiovascular Aspects of Kidney Disease. , 2012, , 2059-2080.		5
106	Commentary: Controversies in NICE guidance on chronic kidney disease. <i>BMJ: British Medical Journal</i> , 2008, 337, a1793-a1793.	2.4	5
107	Renal function: an emerging risk factor for cardiovascular disease?. <i>Evidence-based Cardiovascular Medicine</i> , 2001, 5, 32-33.	0.0	3
108	Investigating modifications to participant information materials to improve recruitment into a large randomized trial. <i>Trials</i> , 2019, 20, 681.	0.7	3

#	ARTICLE	IF	CITATIONS
109	Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply. Lancet, The, 2021, 398, 300.	6.3	3
110	Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomes. Nature Reviews Nephrology, 2009, 5, 126-127.	4.1	1
111	Benefits of lowering cholesterol in chronic kidney disease – Authors' reply. Lancet, The, 2011, 378, 1377-1378.	6.3	1
112	Can vascular mortality be reliably ascertained from the underlying cause of death recorded on a medical death certificate? Evidence from 2800 adjudicated heart protection study (HPS) deaths. Trials, 2015, 16, .	0.7	1
113	Adverse effects of drugs on the development of ischaemic heart disease. Adverse Drug Reaction Bulletin, 2000, 203, 775-778.	0.6	0
114	Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation.. Transplantation, 2014, 98, 155.	0.5	0
115	Methodology for UK recruitment into a large-scale international clinical trial. Trials, 2015, 16, .	0.7	0
116	How was it for you? - obtaining feedback from staff at study sites for the HPS2-thrive trial. Trials, 2015, 16, .	0.7	0
117	Investigating possible fraudulent activity at a research site. Trials, 2015, 16, .	0.7	0
118	Quality by design: using intelligent forms to ensure study protocol compliance and participant safety. Trials, 2015, 16, .	0.7	0
119	Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. Clinica Chimica Acta, 2015, 439, 112-114.	0.5	0